Genmab A/S
Close on Nov 19, 2026
Genmab A/S TEPEZZA Royalty Revenue (from Amgen) by Quarter
TEPEZZA Royalty Revenue (from Amgen) ($M)
Genmab A/S TEPEZZA Royalty Revenue (from Amgen): $36M in Q3 2026, up 20.0% from a year earlier. That is the highest of the 11 quarters on record here.
Where the Q3 2026 figure comes from
“|| TEPEZZA | 36 | 30 | 93 | 75”
Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
Mid-single-digit royalty on worldwide net sales of teprotumumab-trbw (TEPEZZA) for thyroid eye disease.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Genmab A/S TEPEZZA Royalty Revenue (from Amgen) ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/royalties-tepezza
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?